Dr. Louis Weiner on the T-DM1 Mechanism of Action in HER2-Positive Breast Cancer

(57)

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

(1:8)

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

(2:52)

Dr. Esteva Discusses T-DM1 in HER2-Positive Breast Cancer

(2:)

Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast Cancer

(3:51)

HER2CLIMB-02: tucatinib + TDM-1 in advanced breast cancer

(3:15)

Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast Cancer

(1:36)

Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast Cancer

(1:7)

Neoadjuvant T-DM1 in HER2+ Early Breast Cancer

(4:4)

How Breast Cancer Treatment Kadcyla (T-DM1) Works

(3:21)

Dr. Pegram on Early Treatment With T-DM1

(2:2)

EMILIA Trial: T-DM1 in Metastatic Breast Cancer

(4:52)

T-DM1 improves overall survival in previously treated advanced cancer patients

(5:24)

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

(1:20)

Dr. Cheng on the Role of T-DM1 in HER2+ Breast Cancer

(1:14)

Case Review: T-DM1 for Residual HER2+ Breast Cancer

(5:15)

Dr. Kimberly Blackwell Discusses the T-DM1 EMILIA Trial Coprimary Endpoints

(1:4)

Dr. Louis Weiner Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer

(1:21)

Comparing and sequencing T-DM1 and T-DXd in HER2+ breast cancer

(59)

Neratinib/T-DM1 Doses Recommended for Phase II Trial in Breast Cancer

(1:11)